93 related articles for article (PubMed ID: 8763810)
61. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.
Borysiewicz LK; Fiander A; Nimako M; Man S; Wilkinson GW; Westmoreland D; Evans AS; Adams M; Stacey SN; Boursnell ME; Rutherford E; Hickling JK; Inglis SC
Lancet; 1996 Jun; 347(9014):1523-7. PubMed ID: 8684105
[TBL] [Abstract][Full Text] [Related]
62. Clinical studies of human papilloma vaccines in cervical cancer.
Adams M; Borysiewicz L; Fiander A; Man S; Jasani B; Navabi H; Evans AS; Mason M
Adv Exp Med Biol; 2001; 495():419-27. PubMed ID: 11774604
[No Abstract] [Full Text] [Related]
63. Identification of human papillomavirus 16-E6 protein-derived peptides with the potential to generate cytotoxic T-lymphocytes toward human leukocyte antigen-A24+ cervical cancer.
Hara M; Matsueda S; Tamura M; Takedatsu H; Tanaka M; Kawano K; Mochizuki K; Kamura T; Itoh K; Harada M
Int J Oncol; 2005 Nov; 27(5):1371-9. PubMed ID: 16211234
[TBL] [Abstract][Full Text] [Related]
64. Prospects for immunotherapy in cervical cancer.
Immunol Today; 1996 Jul; 17(7):299. PubMed ID: 8763810
[No Abstract] [Full Text] [Related]
65. Towards vaccines against human papillomavirus type-16 genital infections.
Cason J; Khan SA; Best JM
Vaccine; 1993; 11(6):603-11. PubMed ID: 8391738
[TBL] [Abstract][Full Text] [Related]
66. Cancer of the cervix: prospects for immunological control.
Davies DH; McIndoe GA; Chain BM
Int J Exp Pathol; 1991 Apr; 72(2):239-51. PubMed ID: 1849733
[No Abstract] [Full Text] [Related]
67. Vaccine and antibody-directed T cell tumour immunotherapy.
Dermime S; Gilham DE; Shaw DM; Davidson EJ; Meziane el-K; Armstrong A; Hawkins RE; Stern PL
Biochim Biophys Acta; 2004 Jul; 1704(1):11-35. PubMed ID: 15238242
[TBL] [Abstract][Full Text] [Related]
68. Gearing up T-cell immunotherapy in cervical cancer.
Chauhan SR; Bharadwaj M
Curr Probl Cancer; 2018; 42(2):175-188. PubMed ID: 29776594
[TBL] [Abstract][Full Text] [Related]
69. Cervical cancer: prevention, diagnosis, and therapeutics.
Janicek MF; Averette HE
CA Cancer J Clin; 2001; 51(2):92-114; quiz 115-8. PubMed ID: 11577486
[TBL] [Abstract][Full Text] [Related]
70. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer.
van der Sluis TC; van der Burg SH; Arens R; Melief CJ
Curr Opin Immunol; 2015 Aug; 35():9-14. PubMed ID: 26001120
[TBL] [Abstract][Full Text] [Related]
71. Therapeutic vaccines for cervical cancer: dendritic cell-based immunotherapy.
Santin AD; Bellone S; Roman JJ; Burnett A; Cannon MJ; Pecorelli S
Curr Pharm Des; 2005; 11(27):3485-500. PubMed ID: 16248803
[TBL] [Abstract][Full Text] [Related]
72. Immune response to genital papillomavirus infections in women. Prospects for the development of a vaccine against cervical cancer.
Gissmann L; Jochmus I; Nindl I; Müller M
Ann N Y Acad Sci; 1993 Aug; 690():80-5. PubMed ID: 8396380
[No Abstract] [Full Text] [Related]
73.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
74.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
75.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]